- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Health Canada approves conjunctivitis test
Rapid Pathogen Screening Inc. (RPS) has received a Medical Device License from Health Canada for its AdenoPlus, a point-of-care test to help quickly and accurately determine whether a conjunctivitis infection is caused by Adenovirus.
Sarasota, FL-Rapid Pathogen Screening Inc. (RPS) has received a Medical Device License from Health Canada for its AdenoPlus, a point-of-care test to help quickly and accurately determine whether a conjunctivitis infection is caused by Adenovirus.
The Medical Device License will allow the test to be marketed and sold in Canada. The approval follows the product’s successful release in Europe, Asia, and the United States.
As per a worldwide license agreement signed in 2012, the test’s distribution rights in Canada were granted to Nicox, which currently distributes it to eye-care professionals in the United States as well.
“RPS is excited to work with Nicox to bring (the test) to Canada,” said Robert Sambursky, MD, chief executive officer, president, and chairman of RPS.
For more articles in this issue of Ophthalmology Times eReport, click here.
To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.
